Citations

Clear

16281 citation(s) found for "Yu, David".

Lichenoid tissue eruption of the vulva associated with immune checkpoint inhibitor
Davis, Maya , DiCaudo, David J. , Swanson, Leah A. , Davis, Maya I, Davis, Maya I

Mayo Clinic

International Journal of Women’s Dermatology | July 1, 2024 | Volume: 10 | Issue: 3 | Pages: e161

10.1097/jw9.0000000000000161 | PMID 38957413 Get It

P115 Efficacy of mirikizumab in comparison to ustekinumab in patients with moderate-to-severe Crohn’s disease: results from phase 3 VIVID 1 study
Sands, Bruce E, Ferrante, Marc, Hisamatsu, Tadakazu , Kaser, Arthur , Reinisch, Walter , Bragg, Sonja M., Hon, Emily, Lin, Zhantao, Lopes, Michelle Ugolini, Protić, Marijana , Dhesi, Endip , Jairath, Vipul , Bossuyt, Peter , Farraye, Francis A. , Kierkuś, Jarosław , Laharie, David , Reinisch, Walter , Siegmund, Britta , Morris, Nathan , Danese, Silvio

Mayo Clinic

Poster Presentations | July 1, 2024 | Volume: No volume available | Issue: No issue available | Pages: A120.1-A120

10.1136/gutjnl-2024-bsg.197 Get It

Circulating Tumor DNA Predicts Early Recurrence Following Locoregional Therapy for Oligometastatic Colorectal Cancer
O'Donnell, C. , Naleid, Nikolas , Siripoon, Teerada , Zablonski, Kevin , Storandt, Michael H. , Hallemeier, Christopher L. , Conces, Madison , Bajor, David L. , Starlinger, Patrick , Atwell, Thomas D. , Mitchell, Jessica L. , Mahipal, Amit , Jin, Zhaohui , O'Donnell, Conor D J , Zablonski, Kevin G , Starlinger, Patrick , Mitchell, Jessica , Mahipal, Amit , Jin, Zhaohui , Selfridge, Jennifer Eva , Hallemeier, Christopher Leigh , Jethwa, Krishan R. , Thiels, Cornelius A. , Warner, Susanne G.

Mayo Clinic

Cancers | July 1, 2024 | Volume: 16 | Issue: 13 | Pages: 2407

10.3390/cancers16132407 | PMID 39001469 Get It

(1) Background: Local therapies offer a potentially curative approach for patients with oligometastatic colorectal cancer (CRC). An evidence-based consensus recommendation for systemic therapy following definitive locoregional therapy is lacking. Tumor-informed circulating tumor DNA (ctDNA) might provide information to help guide management in this setting. (2) Methods: A multi-institutional retrospective study was conducted, including patients with CRC that underwent curative-intent locoregional therapy to an isolated site of metastatic disease, followed by tumor-informed ctDNA assessment. The Kaplan–Meier method and log-rank tests were used to compare disease-free survival based on ctDNA results. ctDNA test performance was compared to carcinoembryonic antigen (CEA) test results using McNemar’s test. (3) Results: Our study cohort consisted of 87 patients treated with locoregional interventions who underwent ctDNA testing. The initial ctDNA test post-intervention was positive in 28 patients and negative in 59 patients. The median follow-up time was 14.0 months. Detectable ctDNA post-intervention was significantly associated with early disease recurrence, with a median disease-free survival (DFS) of 6.63 months compared to 21.30 months in ctDNA-negative patients (p < 0.001). ctDNA detected a numerically higher proportion of recurrences than CEA (p < 0.097). Post-intervention systemic therapy was not associated with improved DFS (p = 0.745). (4) Conclusions: ctDNA results are prognostically important in oligometastatic CRC, and further prospective studies are urgently needed to define its role in guiding clinical decisions.
H3K27-Altered Diffuse Midline Glioma of the Brainstem: From Molecular Mechanisms to Targeted Interventions
Nonnenbroich, Leo F., Bouchal, Samantha M. , Millesi, Elena , Rechberger, Julian S. , Khatua, Soumen , Daniels, David J. , Daniels, David J , Rechberger, Julian S , Bouchal, Samantha M

Mayo Clinic

Cells | July 1, 2024 | Volume: 13 | Issue: 13 | Pages: 1122

10.3390/cells13131122 | PMID 38994974 Get It

Pediatric high-grade gliomas are a devastating subset of brain tumors, characterized by their aggressive pathophysiology and limited treatment options. Among them, H3 K27-altered diffuse midline gliomas (DMG) of the brainstem stand out due to their distinct molecular features and dismal prognosis. Recent advances in molecular profiling techniques have unveiled the critical role of H3 K27 alterations, particularly a lysine-to-methionine mutation on position 27 (K27M) of the histone H3 tail, in the pathogenesis of DMG. These mutations result in epigenetic dysregulation, which leads to altered chromatin structure and gene expression patterns in DMG tumor cells, ultimately contributing to the aggressive phenotype of DMG. The exploration of targeted therapeutic avenues for DMG has gained momentum in recent years. Therapies, including epigenetic modifiers, kinase inhibitors, and immunotherapies, are under active investigation; these approaches aim to disrupt aberrant signaling cascades and overcome the various mechanisms of therapeutic resistance in DMG. Challenges, including blood–brain barrier penetration and DMG tumor heterogeneity, require innovative approaches to improve drug delivery and personalized treatment strategies. This review aims to provide a comprehensive overview of the evolving understanding of DMG, focusing on the intricate molecular mechanisms driving tumorigenesis/tumor progression and the current landscape of emerging targeted interventions.
Diagnosis of acute myocardial infarction in patients with renal failure using high-sensitivity cardiac troponin T
Knott, Jonathan D , Ola, Olatunde , Michieli, Laura De , Akula, Ashok , Mehta, Ramila A. , Dworak, Marshall , Crockford, Erika, Lobo, Ronstan , Slusser, Joshua P. , Rastas, Nicholas, Karturi, Swetha, Wohlrab, Scott, Hodge, David O. , Grube, Eric , Tak, Tahir , Cagin, Charles , Gulati, Rajiv , Sandoval, Yader , Jaffe, Allan S. , De Michieli, Laura , Slusser, Joshua, Knott, Jonathan , Grube, Eric, Jaffe, Allan S.

Mayo Clinic

European Heart Journal: Acute Cardiovascular Care | June 30, 2024 | Volume: 13 | Issue: 7 | Pages: 546-558

10.1093/ehjacc/zuae079 | PMID 38954535 Get It

Abstract Aims Diagnosing myocardial infarction (MI) in patients with chronic kidney disease (CKD) is difficult as they often have increased high-sensitivity cardiac troponin T (hs-cTnT) concentrations. Methods and results Observational US cohort study of emergency department patients undergoing hs-cTnT measurement. Cases with ≥1 hs-cTnT increase &gt; 99th percentile were adjudicated following the Fourth Universal Definition of MI. Diagnostic performance of baseline and serial 2 h hs-cTnT thresholds for ruling-in acute MI was compared between those without and with CKD (estimated glomerular filtration rate &lt; 60 mL/min/1.73 m2). The study cohort included 1992 patients, amongst whom 501 (25%) had CKD. There were 75 (15%) and 350 (70%) patients with CKD and 80 (5%) and 351 (24%) without CKD who had acute MI and myocardial injury. In CKD patients with baseline hs-cTnT thresholds of ≥52, &gt;100, &gt;200, or &gt;300 ng/L, positive predictive values (PPVs) for MI were 36% (95% CI 28–45), 53% (95% CI 39–67), 73% (95% CI 50–89), and 80% (95% CI 44–98), and in those without CKD, 61% (95% CI 47–73), 69% (95% CI 49–85), 59% (95% CI 33–82), and 54% (95% CI 25–81). In CKD patients with a 2 h hs-cTnT delta of ≥10, &gt;20, or &gt;30 ng/L, PPVs were 66% (95% CI 51–79), 86% (95% CI 68–96), and 88% (95% CI 68–97), and in those without CKD, 64% (95% CI 50–76), 73% (95% CI 57–86), and 75% (95% CI 58–88). Conclusion Diagnostic performance of standard baseline and serial 2 h hs-cTnT thresholds to rule-in MI is suboptimal in CKD patients. It significantly improves when using higher baseline thresholds and delta values.
Benefit of rituximab maintenance after first-line bendamustine-rituximab in mantle cell lymphoma.
Kumar, Anita , Hill, Brian T. , Danilov, Alexey V. , Pongas, Georgios , Greenwell, Irl Brian , Cohen, Jonathon B. , Martin, Peter , Wang, Yucai , Larson, Melissa C. , Bond, David A. , Kahl, Brad S. , Merryman, Reid W. , Grover, Natalie S. , Tun, Aung M. , Ayyappan, Sabarish Ram , Portell, Craig A. , Muñoz, Javier , Reagan, Patrick Michael , Moustafa, Muhamad Alhaj , Pophali, Priyanka A.

Mayo Clinic

Journal of Clinical Oncology | June 28, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 7006-7006

10.1200/jco.2024.42.16_suppl.7006 Get It

7006 Background: Rituximab maintenance (RM) after first-line (1L) bendamustine and rituximab (BR) in MCL did not improve progression-free survival in the MAINTAIN trial (Rummel et al, ASCO 2016) but was associated with improved survival outcomes in a North American observational study (Martin et al, JCO 2023). We sought to examine the potential benefit of RM after BR using a large observational cohort from 26 US academic centers. Methods: Patients with MCL who received 1L BR (without stem cell transplant) outside of clinical trials were included. At the landmark of 3 months after the end of BR, patients who achieved a complete response (CR) or partial response (PR) to BR and had no evidence of progressive disease (PD) or second-line (2L) therapy were deemed eligible for RM. Event-free survival (EFS) was defined as time from landmark to progression, relapse, retreatment, or death. EFS2 was defined as time from landmark to progression, relapse, or retreatment following 2L therapy or death. RM was not considered a line of therapy for either endpoint. OS was defined as time from landmark to death. Survival analysis was done with Kaplan-Meier methods and Cox regression models adjusting for sex and simplified MIPI. Results: Among 796 patients who received 1L BR in 2007-2020, 693 achieved a CR or PR. At the 3-month post-BR landmark, 613 had no evidence of PD, among whom 318 (52%) received RM and 295 did not. The RM group was younger (median age 70 vs 72, p = 0.010) and more predominantly male (78% vs 69%, p = 0.047). There was no statistical difference in stage, simplified MIPI, histology (blastoid or pleomorphic vs classic), Ki-67, TP53 alteration, complex karyotype, year of BR start, or best response to BR between the two groups. The median follow-up after the 3-month post-BR landmark was 61.3 months (95% CI 62.6-70.4). The median number of doses of RM was 10 (IQR 5-12). RM was associated with improved EFS (median 47.1 vs 29.7 months, adjusted HR 0.59, 95% CI 0.48-0.73), EFS2 (median 89.1 vs 48.3 months, adjusted HR 0.63, 95% CI 0.50-0.81), and OS (median 136.1 vs 74.3 months, adjusted HR 0.57, 95% CI 0.44-0.75) (all p values < 0.001). In patients with CR to 1L BR (n=527), 271 (51%) received RM, for a median of 11 (IQR 6-12) doses. In this subgroup, RM was associated with improved EFS (median 60.6 vs 31.5 months, adjusted HR 0.56, 95% CI 0.44-0.71), EFS2 (median 89.1 vs 48.3 months, adjusted HR 0.62, 95% CI 0.48-0.81), and OS (median 136.1 vs 75.6 months, adjusted HR 0.59, 95% CI 0.44-0.79) (all p values < 0.001). Analysis in patients with PR to 1L BR was limited by the sample size (n=86, 47 received RM). The numeric differences in median EFS (20.8 vs 11.5, log-rank p = 0.370), EFS2 (48.9 vs 30.3, log-rank p = 0.210) and OS (87.3 vs 46.9, log-rank p = 0.067) were not statistically significant. Conclusions: In this large multicenter study, RM after 1L BR was associated with improved EFS and OS, supporting its use in routine practice for patients with newly diagnosed MCL.
Exploring systemic treatment approaches for advanced pure large cell neuroendocrine carcinoma (LCNEC): A multicenter retrospective analysis.
Matteson, Kelsey, Ardeshir, Fatemeh, Gray, Jhanelle E. , Espinar, Javier Baena , Grohé, Christian , Pancirer, Danny, Cheung, Justin Matthew, Watson, Alexander, Kaldas, David , Kim, Chul , Awosika, Nichola, Chiang, Anne C. , Nassar, Amin H. , Kwiatkowski, David J. , Nana, Frank Aboubakar , Citarella, Fabrizio , Sridhar, Arthi , Crowley, Fionnuala , Sankar, K. Nathan , Naqash, Abdul Rafeh

Mayo Clinic

Journal of Clinical Oncology | June 28, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 8106-8106

10.1200/jco.2024.42.16_suppl.8106 Get It

8106 Background: Due to lack of prospective data, the optimal first line treatment approach for patients (pts) with pure LCNEC histology remains uncertain. Methods: Across 17 centers, we conducted a retrospective analysis of metastatic pure LCNEC (diagnosed at local institutions) who received 1st-line systemic therapy between 2015-2023. Pts were either treated with chemotherapy (chemo), immunotherapy (IO), or a combination (chemoIO). Clinical outcomes were progression-free survival (PFS), overall survival (OS), objective response rates (ORR), and treatment-related adverse events (trAE) as defined using CTCAE 5.0. Survival analysis by genomic alteration status ( TP53, RB1, STK11, KEAP1, KRAS) and PD-L1 status were performed. Results: We identified 161 pts with median age of 67 years (IQR: 58-83) at 1st line systemic therapy; 54% (n = 87) were males. Median follow-up was 55 months (mo), 62 mo, and 29 mo for the chemo, IO, and chemoIO groups, respectively. 79% (n = 127) were former or current smokers. 1st-line treatments were chemo (n = 94), IO (n = 11), or chemoIO (n = 56). Of 85 pts with PD-L1 status, 58 (68%) were 0% and 27 (32%) were ≥1%. The most common chemo regimen was platinum-etoposide (n = 72, 78%). ChemoIO regimens included carboplatin/etoposide/atezolizumab (n = 23, 43%) and carboplatin/pemetrexed/pembrolizumab (n = 17, 31%). In the IO group, 1 patient received dual IO. Lung (n = 74, 46%) and liver (n = 71, 41%) were the most common sites of metastasisThere was no significant difference in PFS across the groups (median PFS [mPFS] chemoIO: 5.7 mo, 95% CI: 5.0-6.3, chemo: 5.1 mo, 95% CI: 3.1-5.9; IO: 3.6 mo, 95% CI: 1.7-6.5) on multivariable analysis adjusting for ECOG and “M” stage (p = 0.2 and 0.24 for chemoIO-chemo and chemoIO-IO comparisons, respectively). There was no difference in OS (mOS chemo: 11 mo, 95% CI: 7.6-17.4; IO: 13.6 mo, 95% CI: 5.9-not reached; chemoIO: 12.2 mo, 95% CI: 7.4-20.6, p = 0.5 and 0.8 for chemoIO-chemo and chemoIO-IO comparisons, respectively). ORR was 35.2% (31/88) in chemo, 25% (2/8) in IO, and 35.7% (20/56) in chemoIO ( p= 0.46). There were no significant differences in PFS and OS outcomes by treatment group when divided by genetic profile (n = 79, methods), or by PD-L1 status (0% vs ≥1%). Any grade trAE occurred in 48 (51%), 5 (45%), and 28 (50%) pts treated with chemo, IO, and chemoIO, respectively. Grade ≥3 toxicity profiles are shown (table). Conclusions: For 1st-line treatment of LCNEC, similar PFS, OS, and ORR were seen for chemo, IO, and chemoIO. This questions the added benefit of chemoIO compared to chemo alone, and warrants future clinical trials to discern the optimal 1st line treatment. [Table: see text]
The IDH paradox: Meta-analysis of alkylating chemotherapy in IDH -wild type and -mutant lower grade gliomas
Roy, Soumyajit , Brown, Paul D. , DeStephano, David, Canoll, Peter , Qureshi, Summer S., Gallito, Matthew, Sisti, Michael B. , Bruce, Jeffrey N. , Horowitz, David P. , Kachnic, Lisa A. , Neugut, Alfred I. , Cheng, Simon K. , Wang, Tony J. C. , Kinslow, Connor J , Bruce, Jeffrey N , Wang, Tony J C , IWAMOTO, FABIO MASSAITI , Gallito, Matthew, Yu, James B. , Mehta, Minesh P.

Mayo Clinic

Neuro-Oncology | June 28, 2024 | Volume: 26 | Issue: 10 | Pages: 1839-1849

10.1093/neuonc/noae102 | PMID 38943513 Get It

Abstract Background IDH-wild type (-wt) status is a prerequisite for the diagnosis of glioblastoma (GBM); however, IDH-wt gliomas with low-grade or anaplastic morphology have historically been excluded from GBM trials and may represent a distinct prognostic entity. While alkylating agent chemotherapy improves overall survival (OS) and progression-free survival (PFS) for IDH-wt GBM and also IDH-mutant gliomas, irrespective of grade, the benefit for IDH-wt diffuse histologic lower-grade gliomas is unclear. Methods We performed a meta-analysis of randomized clinical trials for World Health Organization (WHO) grades 2–3 gliomas (2009 to present) to determine the effect of alkylating chemotherapy on IDH-wt and -mutant gliomas using a random-effects model with inverse-variance pooling. Results We identified 6 trials with 1204 patients (430 IDH-wt, 774 IDH-mutant) that evaluated alkylating chemoradiotherapy versus radiotherapy alone, allowing us to perform an analysis focused on the value of adding alkylating chemotherapy to radiotherapy. For patients with IDH-wt tumors, alkylating chemotherapy added to radiotherapy was associated with improved PFS (HR:0.77 [95% CI: 0.62–0.97], P = .03) but not OS (HR:0.87 [95% CI: 0.64–1.18], P = .17). For patients with IDH-mutant tumors, alkylating chemotherapy added to radiotherapy improved both OS (HR:0.52 [95% CI: 0.42–0.64], P &lt; .001) and PFS (HR = 0.47 [95% CI: 0.39–0.57], P &lt; .001) compared to radiotherapy alone. The magnitude of benefit was similar for IDH-mutant gliomas with or without 1p19q-codeletion. Conclusions Alkylating chemotherapy reduces mortality by 48% and progression by 53% for patients with IDH-mutant gliomas. Optimal management of IDH-wt diffuse histologic lower-grade gliomas remains to be determined, as there is little evidence supporting an OS benefit from alkylating chemotherapy.
Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial
Vo, Kieuhoa T. , Sabnis, Amit J. , Williams, P. Mickey , Roy‐Chowdhuri, Sinchita , Patton, David R. , Coffey, Brent , Reid, Joel M. , Piao, Jin , Saguilig, Lauren, Jaju, Alok , Fox, Elizabeth , Weigel, Brenda J. , Hawkins, Douglas S. , Mooney, Margaret , Takebe, Naoko , Tricoli, James V. , Janeway, Katherine A. , Seibel, Nita L. , Parsons, D. Williams , Jaju, Alok I , Fox, Elizabeth , Weigel, Brenda J , Hawkins, Douglas S , Mooney, Margaret M , Takebe, Naoko , Tricoli, James V , Janeway, Katherine A , Seibel, Nita L , Parsons, D Williams , Piao, Jin , Reid, Joel M , Roy-Chowdhuri, Sinchita , Patton, David R , Williams, P Mickey , Alonzo, Todd A. , Berg, Stacey L.

Mayo Clinic

JCO Precision Oncology | June 27, 2024 | Volume: No volume available | Issue: 8 | Pages: No page available

10.1200/po.24.00103 | PMID 38935895 Get It

PURPOSE The National Cancer Institute-Children's Oncology Group (NCI-COG) Pediatric MATCH trial assigns patients age 1-21 years with refractory malignancies to phase II treatment arms of molecularly targeted therapies on the basis of genetic alterations detected in their tumor. Patients with activating alterations in the mitogen-activated protein kinase pathway were treated with ulixertinib, an extracellular signal-regulated kinase (ERK)1/2 inhibitor. METHODS As there were no previous pediatric data, ulixertinib was initially tested in a dose escalation cohort to establish the recommended phase II dose (RP2D) before proceeding to the phase II cohort. Ulixertinib was administered at 260 mg/m2/dose orally twice a day (dose level 1 [DL1], n = 15) or 350 mg/m2/dose orally twice a day (DL2, n = 5). The primary end point was objective response rate; secondary end points included safety/tolerability and progression-free survival (PFS). RESULTS Twenty patients (median 12 years; range, 5-20) were treated, all evaluable for response. CNS tumors comprised 55% (11/20) of diagnoses, with high-grade glioma and low-grade glioma most common (n = 5 each). All CNS tumors except one harbored BRAF fusions or V600E mutations. Rhabdomyosarcoma (n = 5) was the most frequent non-CNS diagnosis. DL1 was declared the RP2D in the dose escalation cohort after dose-limiting toxicities in Cycle 1 occurred in 1/6 patients at DL1 and 2/5 patients at DL2, including fatigue, anorexia, rash, nausea, vomiting, diarrhea, dehydration, hypoalbuminemia, and hypernatremia. No objective responses were observed. Six-month PFS was 37% (95% CI, 17 to 58). Three patients with BRAF-altered CNS tumors achieved stable disease >6 months. CONCLUSION Ulixertinib, a novel targeted agent with no previous pediatric data, was successfully evaluated in a national precision medicine basket trial. The pediatric RP2D of ulixertinib is 260 mg/m2/dose orally twice a day. Limited single-agent efficacy was observed in a biomarker-selected cohort of refractory pediatric tumors.
Aseptic Revision Total Hip Arthroplasty Using Modular Fluted Tapered Stems
Carender, Christopher N. , Larson, Dirk R. , Trousdale, Robert T. , Lewallen, David G. , Berry, Daniel J. , Abdel, Matthew P. , Abdel, Matthew P , Larson, Dirk , Berry, Daniel J

Mayo Clinic

Journal of Bone and Joint Surgery | June 27, 2024 | Volume: 106 | Issue: 16 | Pages: 1470-1478

10.2106/jbjs.23.00921 | PMID 38935701 Get It

Background: Modular fluted tapered (MFT) femoral components are frequently utilized in aseptic revision total hip arthroplasties (THAs). However, long-term follow-up has been limited. The purpose of this study was to update our prior series at long-term follow-up, with specific emphasis on implant survivorship, radiographic results, and complications in a large cohort of aseptic revision THAs using MFT stems. Methods: We retrospectively identified 515 aseptic femoral revisions performed with 2 MFT stem designs in the total joint registry of a single tertiary care academic institution from 1999 to 2013. Serial radiographs were reviewed for subsidence of >5 mm. The mean follow-up (and standard deviation) was 10 ± 5 years (range, 2 to 21 years). A competing risk model accounting for death was utilized. Results: The 15-year cumulative incidence of any revision was 12%. There were 57 revisions, 27 of which involved revision of the fluted tapered component (FTC). Dislocation (n = 19), periprosthetic joint infection (n = 15), and aseptic loosening of the FTC (n = 11) were the most common reasons for revision. The 15-year cumulative incidence of any reoperation was 16%. The 15-year cumulative incidences were 6% for any FTC revision and 2% for FTC revision for aseptic loosening. Stem subsidence of >5 mm occurred in 2% of unrevised cases, and all but 1 stem was stable at the most recent follow-up. Conclusions: This large series of MFT stems used in aseptic revision THAs had a 2% incidence of subsequent revision of the FTC for aseptic loosening at 15 years. Dislocation and infection were the most common reasons for any revision. Level of Evidence: Therapeutic Level III . See Instructions for Authors for a complete description of levels of evidence.